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Abstract
Background: Recent studies suggest that cortical lesions in multiple sclerosis (MS) substantially contribute to clinical
disease severity. The present study aimed at investigating clinical, neuroanatomical, and cognitive correlates of these
cortical lesions with a novel approach, i.e. by comparing two samples of relapsing-remitting multiple sclerosis (RRMS)
patients, one group with and the other without cortical lesions.
Methods: High-resolution structural MRI was acquired from 42 RRMS patients and 43 controls (HC). The patient group
was dichotomized based on the presence versus absence of DIR-hyperintense cortex-involving lesions, resulting in a
cortical lesion group (CL, n = 32) and a non-cortical lesion group (nCL, n =10). Cognitive functioning was assessed in all
participants with a comprehensive neuropsychological battery, covering mnestic, executive, and attentional functions.
Results: Highest densities of cortical lesions in the CL group were observed in the bilateral parahippocampal gyrus.
Relative to HC, patients with cortical lesions - but not those without - showed significant global cortical thinning and
mnestic deficits. The two patient groups did not differ from each other regarding demographic and basic disease
characteristics such as EDSS scores.
Conclusion: The appearance of cortical lesions in MS patients is associated with cortical thinning as well as mnestic
deficits, which might be key characteristics of a 'cortically dominant' MS subtype.
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Background
Traditionally, multiple sclerosis (MS) is considered as an
autoimmune inflammatory disorder [1], predominantly
affecting the white matter of the central nervous system
[2]. This view is based on the high sensitivity of conven-
tional MRI sequences in the detection of white matter
abnormalities in MS patients. Nevertheless, histopathologic
analyses of demyelinated foci in the cerebral cortex of
patients with MS - dating back to the beginning of the
20th century [3] - gave first evidence for cortical involve-
ment in MS. In the early 1960s, Brownell and Hughes
described that 26 % of the MS lesions affected the gray
matter [4]. However, the classical view of MS as a pure
white matter pathology has not been overcome until the
beginning of the 21st century. Due to the introduction of
more sensitive imaging techniques such as double inver-
sion recovery (DIR), gray matter involvement of the MS
pathology is now well established [5, 6]. By suppressing the
signals form the cerebrospinal fluid and white matter, DIR
sequences have a higher sensitivity compared to conven-
tional MR sequences [4] and thus, have made a major
contribution in detecting focal cortical lesions in MS.
Although a recent study has shown that DIR can detect
only a minority of cortical lesions in MS, the same study
has also shown a significant correlation between the num-
ber of DIR-hyperintense cortical lesions on the one hand
and the total number of cortical lesions in post-mortem
histopathologic analysis on the other hand [7]. Moreover,
DIR is currently considered the best wide-scale application
pulse sequence for cortical lesion detection and offers high
sensitivity, specificity and accuracy for the detection of gray
matter lesions [8].
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Multiple sclerosis is associated with a variety of symp-
toms that are responsible for functional impairment in
affected patients. Besides physical disability, cognitive defi-
cits – which were firstly described in the second half of the
19th century [9] – are found in up to 70 % of patients with
multiple sclerosis at both the earlier and later stages of the
disease [10]. MS-related cognitive impairment can affect
various aspects of cognition. Processing speed and episodic
memory seem most commonly affected [11]. However, MS
patients often exhibit significant deficits in executive func-
tions too [12, 13].
The extended focus in MS research including gray matter
pathology had important consequences for the study of the
neural correlates of MS symptoms. In recent years, the con-
tribution of DIR-hyperintense cortical lesions to functional
loss is particularly highlighted. Cross-sectional and longitu-
dinal studies have shown correlations between the number
and/or volume of cortical lesions and cognitive [14, 15] or
physical [16] impairment. Regional associations are also
described, for instance between an accumulation of cortical
lesions in mesio-temporal areas and impairments in
episodic memory [12, 17].
However, these studies are not without limitations. For
example, detailed cognitive investigation [14] or DIR
sequences were lacking [15]. Here we try to overcome
these shortcomings and apply a novel methodological
approach to investigate the clinical relevance of cortical
lesions in MS, i.e. by dichotomizing patients based on
the presence or absence of cortical lesions. The resulting
two subgroups were compared with regard to demog-
raphy, cognition, fatigue, affective mood state, and
several other established MRI markers of disease sever-




Forty-two patients with a diagnosis of relapsing-remitting
multiple sclerosis (RRMS) according to the McDonald
2010 criteria [18] were recruited at the Multiple Sclerosis
Centre of the University Hospital of Zurich. Patients with
at least one DIR-hyperintense cortex-involving lesion were
assigned to the cortical lesion group (CL group, n = 32),
the remaining patients formed the non-cortical lesion
group (nCL group, n = 10). All patients received immuno-
modulatory treatment - 30 with natalizumab, seven with
beta-interferons, three with fingolimod, one with glatira-
mer acetat and one with dimethylfumarate. Exclusion cri-
teria were a relapse or steroid-treatment during the last
two months, current or past neurological disorders in
addition to multiple sclerosis, and psychiatric disorders
apart from MS-related depressive mood state. Moreover,
none of the patients was affected by severe visual deficits
or upper limb sensorimotor impairment that could hinder
cognitive test performance. Furthermore, 43 age-, gender-,
handedness- and education-matched healthy control
persons (HC) without previous or present history of
neurological or psychiatric diseases were included. Con-
trols received financial compensation for their attendance.
MRI data acquisition
The MR scan was performed within one month of the
neurological and neuropsychological examinations. All
images were acquired using a 1.5-T scanner (Siemens
Magnetom Avanto™) equipped with a SQ-engine gradient
(45 m/T/m @ 200 T/m/s), using a dedicated 32-channel
head coil. No hardware upgrades of the scanner occurred
during the study period. The following sequences were per-
formed in all subjects: (1) 3D Double Inversion Recovery
(DIR) (voxel size = 1.5 x 1.5 x 1.5 mm, slice thickness =
1.5 mm, repetition time = 7500 ms, echo time = 308 ms,
inversion timing 1 = 3000 ms, inversion timing 2 = 450 ms);
(2) 3D T1-weighted MPRAGE (voxel size = 1 x 1 x 1 mm,
slice thickness = 1 mm, repetition time = 2420 ms, echo
time = 4.18 ms), and (3) 3D FLAIR (voxel size = 0.9 x 0.9 x
2.0 mm, slice thickness = 2 mm, repetition time = 5000 ms,
echo time = 342 ms, inversion time = 1800 ms).
MRI post-processing and statistical analysis
The classification of cortical lesions was conducted
according to the consensus recommendations of Geurts
and colleagues [19]. Consequently, cortical lesions were
defined as those lesions appearing hyperintense on DIR
images compared to surrounding normal-appearing gray
matter, entirely or partly located in the cortical gray
matter and occupying at least three voxels. Juxtacortical
lesions (lesions not entering, but neighboring the cortical
mantle) were not scored. DIR-hyperintense lesions were
identified and manually delineated with MRIcron (http://
people.cas.sc.edu/rorden/mricron/index.html), which was
further used to measure total cortical lesion volume. An
experienced rater, supervised by a neuroradiologist,
assessed all images. The same procedure was applied to
FLAIR images in order to identify FLAIR-hyperintense le-
sions. We used Statistical Parametric Mapping (SPM8,
http://www.fil.ion.ucl.ac.uk/spm/) to co-register and
normalize the individual lesion maps to MNI (Montreal
Neurological Institute) standard space according to the
normalization procedure proposed by Crinion and col-
leagues [20]. Normalized binary lesion maps were than
plotted with MRIcron onto a T1-weighted MNI template
brain to create lesion overlap plots. Central brain atrophy
was examined by measuring the width of the third ven-
tricle (TVW) according to the procedure proposed by
Benedict and colleagues [21]. Brain parenchymal fraction
(BPF), calculated as the ratio of brain parenchymal tissue
volume to the total intracranial volume, was used as a
measurement of whole-brain atrophy. The calculation was
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performed with Jim software (Xinapse Systems Ltd.,
Northants (UK); http://www.xinapse.com). Global cortical
thickness evaluation was performed with the semi-
automated Freesurfer image analysis suite based on
MPRAGE images, which is documented and freely avail-
able online (https://surfer.nmr.mgh.harvard.edu/). Further
information and technical details of these procedures are
described in prior publications [22, 23]. To detect possible
misclassifications of white and gray matter due to multiple
sclerosis lesions, all images were visually inspected after
the white/gray matter segmentation. In two patients, a
semi-automated correction of topological defects was re-
quired. We used the manual procedure of control points,
which is implemented in the Freesurfer software package.
No further lesion masking was needed in order to obtain
accurate reconstructions of the pial and the white matter
surfaces.
Clinical and neuropsychological assessment
All patients underwent neurological status examination,
including the Expanded Disability Status Scale (EDSS).
Cognitive functions were assessed with a comprehensive
battery of validated and standardized neuropsychological
tests. To minimize the issue of multiple statistical testing,
composite index scores were computed for mnestic,
executive and attentional functions by averaging z-scores
for all subtests of the corresponding function [24]. An
overview of the indices is shown in Additional file 1. The
mnestic index score was derived from the delayed free re-
call and recognition of a 15-item word list [25] as well as
the delayed free recall and recognition of a previously
copied complex geometric figure [26]. Phonemic-verbal
[27] and figural fluency [28], response inhibition [29] and
cognitive flexibility [29] formed the executive index. The
attentional index was based on processing speed during
color naming [29] as well as on reaction times from tasks
measuring alertness and selective attention [30]. More-
over, participants had to complete a German version [31]
of the CES-D Depression questionnaire [32] and the
Würzburg Fatigue Inventory (WEIMuS) [33] to self-rate
depressive symptoms as well as fatigue during the last
week. Similar to other studies [34], cognitive reserve was
examined with passive vocabulary knowledge (multiple
choice word test) [35].
Statistical analysis
Statistical analyses were performed with SPSS (IBM,
Chicago, USA, Version, 21.0, https://www.ibm.com/
marketplace/cloud/statistical-analysis-and-reporting). Un-
less otherwise stated, a p-level below 5 % was considered
statistically significant. Assumptions for normality were
tested for all continuous data with Kolmogorov-Smirnov
tests. In case of normally distributed variables, a multivari-
ate ANOVA was used to compare groups. Bonferroni cor-
rection was applied for post-hoc analyses. When variables
were not normally distributed, non-parametric tests were
applied (Mann–Whitney U, Kruskal-Wallis).
Results
Demographic and clinical variables
Demographic and clinical characteristics of the three
groups are reported in Table 1. No between-group differ-
ences were found with regard to age, education, cognitive
reserve and gender. Furthermore, EDSS, age at diagnosis,
and disease duration did not differ significantly between CL
and nCL patients.
MRI markers
We detected cortical lesions in 32 of 42 patients (76 %).
The highest occurrence of cortical lesions was found
bilaterally in the parahippocampal gyrus (Fig. 1). Twenty-
five percent of the CL patients showed at least one cortical
lesion in this region. An overview of the atrophy measure-
ments in the three groups is given in Fig. 2. The three
groups differed significantly from one another with regard
to BPF (F(2) = 22.4, p < 0.001), TVW (H(2) = 20.9, p <
0.001) and global cortical thickness (F(2) = 11.6, p < 0.001).
Bonferroni-corrected post-hoc analyses revealed a reduc-
tion of BPF in CL patients relative to HC (p < 0.001) as well
as an enlarged TVW (p < 0.001). In contrast, the BPF and
TVW values of nCL patients did not differ from those of
CL patients or controls. Furthermore, Bonferroni-corrected
Table 1 Demographic and disease characteristics of multiple sclerosis patients and healthy controls
nCL group (n = 10), Mean (SD) CL group (n = 32), Mean (SD) Controls (n = 43), Mean (SD) Test p-value
Age, years 32.6 (9.98) 38.22 (7.2) 36.1 (8.29) One-way ANOVA 0.155
Education, years 15.5 (3.1) 14.45 (3.2) 14.58 (2.4) KW 0.408
Cognitive reservea 30.0 (3.1) 30.94 (3.4) 30.70 (2.3) KW 0.689
EDSS 2.0 (1.8) 2.8 (1.8) – MW-U 0.174
Age at diagnosis, years 26.7 (9.7) 30.65 (7.6) – t-test 0.185
Disease duration, years 65.5 (59.6) 85.31 (68.9) – MW-U 0.570
Abbreviations: nCL patients without cortical lesions, CL patients with cortical lesions, one-way ANOVA one-way analysis of variance, EDSS Expanded Disability Status
Scale, KW Kruskal-Wallis, MW-U Mann–Whitney U
aCognitive reserve was examined with passive vocabulary knowledge (multiple choice word test)
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post-hoc analyses revealed a reduction of global cortical
thickness in CL patients compared to HC (p < 0.001) and
nCL (p = 0.029) patients, while HC and nCL patients did
not differ from one another. Regarding the FLAIR-
hyperintense lesion volume, no significant difference (p =
0.064) was observed between the two patient groups.
Cognitive test results, fatigue and depression
questionnaires
The attentional index did not differ significantly between
the three groups (F(2) = 1.207, p = 0.304). In contrast, a
group effect was observed for the executive index (H(2)
= 22.476, p < 0.001). Both patient groups showed
Fig. 1 Spatial distribution of cortex-involving lesions in the CL patient group. Overlap plot based on all normalized cortex-involving lesions found in all
CL patients. Lesion frequency across the sample is displayed for every depicted voxel. The bar indicates the number of patients showing
damage to a particular voxel. a) Axial and coronal views of lesion frequency. b) and c) Highest lesion overlap was found in the bilateral
parahippocampal gyrus (MNI coordinates in b). Image orientation follows the radiological convention (right on left side)
Fig. 2 Atrophy measurements. Bars depict mean z-scores (and standard errors) of patients with (CL) and without cortex-involving (nCL) lesions as
well as of healthy controls (HC). Note that the two patient groups differed only in global cortical thickness
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executive dysfunction compared to HC (CL vs. HC: Z(2)
= −4.272, p < 0.001; nCL vs. HC: Z(2) = −3.197, p <
0.001), but did not differ from one another (Z(2) =
−0.251, p = 0.805). Furthermore, there was a main group
effect for mnestic functions (F(2) = 7.667, p < 0.001).
Bonferroni-corrected post-hoc analyses revealed that the
CL group performed significantly worse in memory tests
than both nCL patients (p = 0.031) and HC (p < 0.001),
whereas nCL patients did not differ from HC in this
regard. Figure 3 depicts the three cognitive indices and
corresponding differences between groups. According to
supplemental analyses (summarized in Additional file 2)
of the individual tests pooled in the memory index,
differences between the two patient groups were most
strongly pronounced in figural recognition. No main
group effect was observed for depression (H(2) = 5.634,
p = 0.060). However, both patient groups showed signifi-
cantly enhanced fatigue scores compared to HC (CL vs.
HC: Z(2) = −2.319, p = 0.020; nCL vs. HC: Z(2) = −2.102,
p = 0.036), but did not differ from one another in this
regard (Z(2) = −0.445, p = 0.673).
Discussion
The impact of gray matter pathology, in particular that of
gray matter lesions, on cognitive and physical functioning
in MS patients has been discussed for many years. Here
we highlight the clinical relevance of DIR-hyperintense
cortical lesions in patients with RRMS. The most
intriguing finding of the present study was that patients
with - compared to those without visible cortical lesions -
differed from each other in global cortical thickness and
mnestic functions, whereas no differences between these
two patient groups were observed regarding EDSS, age,
age at diagnosis, disease duration, or non-mnestic cogni-
tive functions. Moreover, patients without cortical lesions
showed normal cortical thickness and mnestic functions,
when compared with a group of healthy controls.
That a reduction of cortical thickness can occur in MS
[36] - and that this thinning is related to global e.g. [37]
and even specific cognitive impairment [12, 38] - has been
found in previous studies. Similar to a recent finding [39],
we show an association between MS-related cortical thin-
ning and the presence of cortical MS lesions. It is known
that gray matter pathology involves both inflammatory
and degenerative mechanisms, but the relationship
between the two remains unclear [6]. Gray matter atrophy
might be the final step of several pathological processes,
which could include cortical demyelination but also retro-
grade degeneration secondary to white matter lesions and,
perhaps, primary neurodegeneration [40].
We detected DIR-hyperintense cortical lesions in 76 %
of our RRMS patients, supporting the notion of a high
prevalence of these lesions [16]. In further agreement with
previous findings [41], we observed an uneven spatial
distribution of cortical lesions over the cerebral cortex,
with a prominent accumulation in memory-relevant
Fig. 3 Indices of cognitive performance. Bars show mean z-scores (and standard errors) of patients with (CL) and without cortex-involving (nCL)
lesions as well as of healthy controls (HC). Note that the two patient groups differed only in mnestic functioning
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mesiotemporal regions, particularly in the bilateral parahip-
pocampal gyrus. While the importance of the hippocam-
pus for memory function is known since the classical
description of the patient H.M. in 1957 [42], parahippo-
campal involvement in memory functions was recognized
only two decades ago [43]. Squire and Zola-Morgen identi-
fied the anatomical components of what is termed the
medial temporal memory system [44]. By now it is well
known that bilateral damage to the medial temporal lobe
causes severe learning and memory impairments. This
relationship has also been shown in MS patients. Learning
and memory is the most frequently disrupted cognitive
domain in MS, reported in 40–60 % of patients [45].
Moreover, Coebergh et al. [46] described a patient with
acute memory impairment, associated with hippocampal
and cortical lesions. Cortical lesions were also associated
with cognitive decline in a group of 13 MS patients [17].
In this study, a significant correlation between hippocam-
pal lesion load and visuospatial memory was observed.
Based on the present and previous findings, we thus
conclude that mesiotemporal cortical lesions are highly
prevalent in RRMS patients and play a crucial role in the
development of mnestic dysfunction.
The association we found between memory impairment
and both cortical thinning as well as cortical lesions seems
particularly intriguing: One might speculate that mnestic
dysfunction in MS patients could indicate cortical involve-
ment of the MS pathology in general. Related to this
assumption, a rarely occurring variant of so-called 'cortical
MS' has been described in previous studies [47, 48]. The
condition was predominantly characterized by the
presence of neurobehavioral symptoms (e.g. depression,
apathy) and neuropsychological deficits (e.g. agraphia,
anomia) suggesting cortical dysfunction. However, detailed
and explicit imaging data for detecting cortical involve-
ment (e.g. DIR) is missing in these studies. By approaching
from the imaging side, our patient group with cortical
involvement may reflect a different and somehow incom-
plete variant of cortical MS, as they showed distinct mnes-
tic deficits in association with cortical involvement, but no
other cortical symptoms such for example depression.
Moreover, we found no patient with cortical lesions in the
absence of subcortical lesions. In all patients, including
those of the CL group, the majority of MS lesions was
located subcortically. Taking this into account, we here
propose that our CL group may represent a 'cortically
dominant' subtype of MS. In these patients, pathophysio-
logical processes might be different from those of patients
without cortical involvement.
Beside the difference between the two patient groups in
mnestic functions, both patient group showed executive
deficits compared to the healthy control group. This find-
ing is in line with previous studies that have shown signifi-
cant executive dysfunction in MS patients [12, 13, 49].
Much research and clinical development in MS has
focused on the inflammatory mechanisms of the disease.
Meanwhile, multiple disease-modifying drugs (DMD)
are available that target the inflammatory pathology of
MS, in particular the development of new white matter
lesions [50]. A recent study demonstrated that DMD -
in particular IFN β-1a and glatiramer acetate - can
reduce the accumulation of cortical lesions too [51]. In
addition, Filippi and colleagues [52] showed that the
presence of at least one cortical lesion is associated with a
high risk of conversion from clinically isolated syndrome
(CIS) to definite MS within a short period. Together with
our results, these findings highlight the relevance of
cortical lesions as a “target” in the development of new
DMD, and to include cortical lesions as a primary out-
come variable in disease and treatment monitoring.
This study is not without limitations. As already men-
tioned earlier, DIR represents only a limited snapshot of
the real cortical pathology that is present in MS patients.
The combination of DIR and a T1-weighted phase-
sensitive inversion recovery (PSIR) sequence would sub-
stantially improve the sensitivity of detecting lesions
present in the cortex of MS patients [53]. Moreover, the
present analyses are limited due to the low MRI field
(1.5 T) applied. It has been shown that high field (3 T)
and ultra-high field (7 T) MRI systems deliver a higher
detection rate of cortical lesions in vivo [54]. Finally, a
further limitation of the present study is the relatively
small and unbalanced sample size.
Conclusion
In conclusion, the occurrence of cortical lesions in MS
is clinically relevant insofar as it is associated with
neurodegenerative cortical thinning and mnestic dys-
function. Although with today’s imaging techniques, it
is only possible to visualize the 'tip of the iceberg' of
cortical MS lesions [7, 55], further progress in detec-
tion algorithms can be expected and will likely im-
prove our understanding of MS pathology, symptoms,
and treatment.
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